Table 4. Univariate and multivariate analysis for pathological response to neo-adjuvant chemotherapy in IBC.

Characteristics	Univariate analysis			Multivariate analysis
	N	OR [CI95]	p-value	N	OR [CI95]	p-value
Age, years > 50 vs. <=50	64	0.72 [0.29–1.72]	0.533
Histological type, other vs. ductal	64	0.38 [0.04–1.94]	0.392
Histological grade, 3 vs. 2	60	1.11 [0.42–3.05]	0.859
ER status, positive vs. negative	66	0.58 [0.24–1.37]	0.296
PR status, positive vs. negative	66	0.36 [0.14–0.86]	0.059	66	0.49 [0.17–1.38]	0.258
ERBB2 status, positive vs. negative	66	0.48 [0.15–1.3]	0.247
Molecular subtypes, ERBB2-enriched vs. basal	66	0.95 [0.28–3.18]	0.947
Luminal A vs. basal	66	0.24 [0.05–0.94]	0.110
Luminal B vs. basal	66	0.67 [0.16–2.55]	0.627
Normal-like vs. basal	66	0.5 [0.12–1.81]	0.391
PDL1 group, high vs. Low	66	3.44 [1.42–8.63]	2.33E–02	66	3.49 [1.28–10.1]	4.46E–02
FAC/T response signature, “pCR-predicted” vs. “no pCR-predicted”	66	3 [1.22–7.54]	4.60E-02	66	1.58 [0.53–4.7]	0.487
Stromal signature, “pCR-predicted” vs. “no pCR-predicted”	66	2.86 [1.18–7.08]	0.052	66	3.28 [1.25–9.17]	0.047